Trade Aligos Therapeutics, Inc. - ALGS CFD

Add to favourite

14.2158

4.67%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.3284

Long position overnight fee

-0.026235%

Short position overnight fee

0.004012%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	13.7058
Open	14.0258
1-Year Change	1658.5%
Day's Range	14.0258 - 14.7658

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Sep 17, 2024	13.7058	-0.4600	-3.25%	14.1658	14.8658	13.5458
Sep 16, 2024	14.2158	0.1800	1.28%	14.0358	14.7958	14.0258
Sep 13, 2024	14.3258	0.6500	4.75%	13.6758	14.9158	13.6758
Sep 12, 2024	13.7358	-0.5600	-3.92%	14.2958	16.2658	13.0958
Sep 11, 2024	13.7258	-0.0400	-0.29%	13.7658	14.5758	13.2358
Sep 10, 2024	13.5980	-4.4000	-24.45%	17.9980	17.9980	12.7280
Sep 9, 2024	18.9980	6.7900	55.62%	12.2080	19.2880	12.0780
Sep 6, 2024	12.0980	0.6200	5.40%	11.4780	12.4380	11.2780
Sep 5, 2024	11.8380	0.4400	3.86%	11.3980	11.9080	11.1980
Sep 4, 2024	11.5480	-0.4400	-3.67%	11.9880	12.0480	11.4780
Sep 3, 2024	11.6980	-0.8000	-6.40%	12.4980	12.4980	11.2980
Aug 30, 2024	12.5080	-0.2700	-2.11%	12.7780	12.9080	12.3880
Aug 29, 2024	13.0480	0.2400	1.87%	12.8080	13.6980	12.7780
Aug 28, 2024	12.7980	0.0000	0.00%	12.7980	13.0980	12.7480
Aug 27, 2024	13.1280	-0.0100	-0.08%	13.1380	13.3480	12.4480
Aug 26, 2024	13.3180	-0.2400	-1.77%	13.5580	13.6780	13.0980
Aug 23, 2024	13.7080	0.2100	1.56%	13.4980	13.7780	13.4980
Aug 22, 2024	13.6980	0.0000	0.00%	13.6980	14.0980	13.1280
Aug 21, 2024	13.7380	-0.1600	-1.15%	13.8980	14.1880	13.3480
Aug 20, 2024	14.2380	0.2300	1.64%	14.0080	14.3780	13.8980

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Aligos Therapeutics, Inc. Company profile

About Aligos Therapeutics Inc

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). It developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The Company's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Aligos Therapeutics Inc revenues increased from $0K to $4.4M. Net loss increased 18% to $128.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 12% to $88.3M (expense), Stock-based Compensation in R&D increase from $1M to $7.6M (expense).

Industry:

Biotechnology & Medical Research (NEC)

One Corporate Dr., 2Nd Floor
2nd Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

News

Bank of Japan Preview

The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.

09:40, 17 September 2024

FOMC Decision Preview

As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.

09:48, 16 September 2024

ECB Preview: cuts expected but the pace is uncertain

Markets expect the ECB to cut rates again in September, but how many more?

12:34, 11 September 2024

Market analysis: US CPI and PPI

Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.

07:56, 10 September 2024

Introducing Newsquawk: your new in-platform newsfeed

We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.

14:09, 20 August 2024